CARE 2022
Basic and Clinical Sciences, Crystal-induced Arthropathies, Infections and Related Arthritides, Metabolic Bone Disease, Osteoarthritis and Related Disorders, Rheumatoid Arthritis, Seronegative Spondyloarthropathies, Other Rheumatic and Connective Tissue Disorders (ORCT), Lupus Erythematosus, Nonarticular and Regional Musculoskeletal Disorders, Nonrheumatic Systemic Disorders, Vasculitides
Tuesday, October 11, 2022, 12:00 AM
Saturday, October 11, 2025, 11:55 PM
CME, MOC, Participation
CARE Member Discount
CARE 2021, CARE 2020, CARE 2022
You need to add at least one item to your cart to receive this discount.
CARE Member Discount -40%

Discounted Rate Coupon Codes

Discounted rate coupon codes are available upon request for the following individuals by contacting

  • ACR FIT Members
  • ACR FIT Nonmembers
  • ACR Member Program Director 
  • ACR Nonmember Program Director
  • CARE 2022 Developers
  • CARE 2022 Beta Tester (Completions Only)

Activity Information

Assess your rheumatology medical knowledge and enhance your patient care. With CARE 2022, you receive:

  • 60 case-based, multiple-choice questions with in-depth answer rationales
  • Images and educational links
  • 20.0 ABIM MOC points and 20.0 AMA PRA Category 1 Credit(s)™ with a passing score of 70% or higher

Target Audience

Rheumatologists, physicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Recognize clinical presentations of rheumatologic conditions
  • Select appropriate tests in the diagnosis, staging, or follow-up of rheumatologic conditions
  • Recommend appropriate management for rheumatologic conditions
  • Assess risk in rheumatologic conditions
  • Understand pathophysiology and basic science relevant to the care of patients with rheumatologic conditions

CME and MOC Information

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The ACR designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board(s).


Faculty and Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at

Nature of Financial Relationships

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience all financial relationships with ineligible companies any financial or other relationship(s) with a ineligible company including, but not limited to:

  1. Advisor or review panel member
  2. Consultant
  3. Employee
  4. Officer or Board Member
  5. Grant/research support
  6. Speaker/honoraria includes speakers bureau, symposia, and expert witness
  7. Independent contractor
  8. Ownership Interest
  9. Royalties
  10. Intellectual property/patents
  11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
  12. Other financial or material support

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

The CARE Development Group and faculty reported the following disclosures.

CARE Development Group Members

The following CARE Development Group members have no relevant financial relationship(s) with ineligible companies to disclose.

  • Joel Hirsh, MD
  • Jonathan Cheah, MD
  • Alan Erickson, MD
  • Rumey Ishizawar, MD
  • Deana Lazaro, MD
  • Jennifer Medlin, MD
  • Abhishek Nandan, MD
  • Mathilde Pioro, MD
  • Amanda Sammut, MD
  • Jennifer Stichman, MD
  • Jessica Bloom, MD
  • Lisa Davis, MD
  • Sarah Fantus, MD
  • Alison Gizinski, MD
  • Melissa Griffith, MD
  • Arundathi Jayatilleke, MD
  • Tate Johnson, MD
  • Fotios Koumpouras, MD
  • Bharat Kumar, MD
  • Jean Liew, MD
  • Amanda Lusa, MD
  • Seema Malkana, DO
  • Yevgeniy Popov, MD
  • Kai Sun, MD
  • Nicole Walton, DO

The following planning committee members have relevant financial relationship(s) with ineligible companies to disclose.

  • Bryant England, MD - Boehringer-Ingelheim2
  • Angela Robinson, MD - Pfizer5 (children are enrolled in Pfizer COVID vaccine trial as participants) 
  • Beth Rubinstein, MD - Amgen11; General Electric Co11; Bristol Myers Squibb11
  • Matthew Carroll, MD, FACP, FACR - Boehringer-Ingelheim1,4; Exagen6; Flexion6; Gilead1,4 
  • Prateek Gandiga, MD, FACP - Alexion Pharmaceuticals(site investigator); Kezar Pharmaceuticals7 (site investigator) 
  • Vikram Garg, MD - Novartis3

*All of the relevant financial relationships listed for these individuals have been mitigated.

Corporate Support 

Educational grant support for this activity has been provided by AbbVie, Inc. and Bristol-Myers Squibb.